Shares of Sienna Biopharmaceuticals Inc (NASDAQ:SNNA) were down 33.2% during trading on Wednesday . The stock traded as low as $0.17 and last traded at $0.13, approximately 7,434,451 shares changed hands during mid-day trading. An increase of 341% from the average daily volume of 1,687,153 shares. The stock had previously closed at $0.19.
A number of analysts recently weighed in on SNNA shares. BMO Capital Markets decreased their price target on shares of Sienna Biopharmaceuticals to $3.00 and set an “outperform” rating for the company in a research note on Thursday, September 5th. ValuEngine cut shares of Sienna Biopharmaceuticals from a “buy” rating to a “hold” rating in a report on Friday, October 25th. Finally, Zacks Investment Research downgraded shares of Sienna Biopharmaceuticals from a “buy” rating to a “hold” rating in a research note on Tuesday, November 19th.
The business has a 50-day simple moving average of $0.19 and a two-hundred day simple moving average of $0.61. The company has a market capitalization of $6.77 million, a price-to-earnings ratio of -0.04 and a beta of 2.67.
Several large investors have recently added to or reduced their stakes in SNNA. FMR LLC lifted its holdings in shares of Sienna Biopharmaceuticals by 41.6% during the first quarter. FMR LLC now owns 4,489,690 shares of the company’s stock worth $10,416,000 after purchasing an additional 1,318,675 shares during the period. Vanguard Group Inc. raised its position in Sienna Biopharmaceuticals by 95.3% during the 2nd quarter. Vanguard Group Inc. now owns 1,859,306 shares of the company’s stock worth $1,617,000 after buying an additional 907,318 shares during the last quarter. Renaissance Technologies LLC raised its position in Sienna Biopharmaceuticals by 92.1% during the 2nd quarter. Renaissance Technologies LLC now owns 586,294 shares of the company’s stock worth $510,000 after buying an additional 281,094 shares during the last quarter. Paloma Partners Management Co acquired a new stake in shares of Sienna Biopharmaceuticals in the 2nd quarter worth $60,000. Finally, Jane Street Group LLC acquired a new stake in shares of Sienna Biopharmaceuticals in the 2nd quarter worth $50,000. 17.36% of the stock is currently owned by institutional investors and hedge funds.
Sienna Biopharmaceuticals Company Profile (NASDAQ:SNNA)
Sienna Biopharmaceuticals, Inc, a clinical-stage biopharmaceutical company, focuses on the development of drugs in various therapeutic areas. It develops therapies in immunology and inflammation that target select pathways in tissues, such as skin. The company's lead product candidates include SNA-120, a first-in-class inhibitor of tropomyosin receptor kinase A, which is in a Phase IIb clinical trial for the treatment of psoriasis and associated pruritus; and SNA-125, a topical dual Janus kinase 3 inhibitor that is in Phase I/II clinical trials for the treatment of atopic dermatitis, psoriasis, and pruritus.
Featured Story: Why is the price-sales ratio important?
Receive News & Ratings for Sienna Biopharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Sienna Biopharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.